74 related articles for article (PubMed ID: 7286558)
1. Increase in the cytotoxicity of 1-beta-D-arabinofuranosylcytosine due to inhibition of degradation of its triphosphate by hydroxyurea in Burkitt's lymphoma cells.
Abe I; Saito S; Suzuki M; Sato H
Gan; 1981 Apr; 72(2):337-8. PubMed ID: 7286558
[No Abstract] [Full Text] [Related]
2. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
[TBL] [Abstract][Full Text] [Related]
3. Prediction of sensitivity to 1-beta-D-arabinofuranosylcytosine by the plateau level of its 5'-triphosphate in human lymphoblastic cell lines in vitro.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Eur J Cancer Clin Oncol; 1983 Jul; 19(7):941-4. PubMed ID: 6576907
[TBL] [Abstract][Full Text] [Related]
4. Ara-CTP metabolism following hydroxyurea or methotrexate treatment in human leukemia cell lines.
Kubota M; Takimoto T; Kitoh T; Tanizawa A; Akiyama Y; Kiriyama Y; Mikawa H
Adv Exp Med Biol; 1989; 253B():363-7. PubMed ID: 2610124
[No Abstract] [Full Text] [Related]
5. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Paul CY; Gahrton CG; Peterson CO
Cancer Res; 1985 May; 45(5):2373-5. PubMed ID: 3986778
[TBL] [Abstract][Full Text] [Related]
6. Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts.
Jamieson GP; Finch LR; Snook M; Wiley JS
Cancer Res; 1987 Jun; 47(12):3130-5. PubMed ID: 3472653
[TBL] [Abstract][Full Text] [Related]
7. Differential modulation of 1-beta-D-arabinofuranosylcytosine metabolism by hydroxyurea in human leukemic cell lines.
Kubota M; Takimoto T; Tanizawa A; Akiyama Y; Mikawa H
Biochem Pharmacol; 1988 May; 37(9):1745-9. PubMed ID: 2454114
[TBL] [Abstract][Full Text] [Related]
8. Dephosphorylation of nucleotides of 1-beta-D-arabinofuranosylcytosine in relation to the different drug sensitivity in tumor cells.
Abe I; Sato H
Tohoku J Exp Med; 1979 Mar; 127(3):281-8. PubMed ID: 442078
[No Abstract] [Full Text] [Related]
9. Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.
Rustum YM; Preisler HD
Cancer Res; 1979 Jan; 39(1):42-9. PubMed ID: 282940
[No Abstract] [Full Text] [Related]
10. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.
Plunkett W; Iacoboni S; Keating MJ
Scand J Haematol Suppl; 1986; 44():51-9. PubMed ID: 3457439
[No Abstract] [Full Text] [Related]
11. Inability of liposome encapsulated 1-beta-D-arabinofuranosylcytosine nucleotides to overcome drug resistance in L1210 cells.
Rustum YM; Mayhew E; Szoka F; Campbell J
Eur J Cancer Clin Oncol; 1981 Jul; 17(7):809-17. PubMed ID: 7199474
[No Abstract] [Full Text] [Related]
12. Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity.
Rauscher F; Cadman E
Cancer Res; 1983 Jun; 43(6):2688-93. PubMed ID: 6189585
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.
Roberts D; Peck C; Hilliard S; Wingo W
Cancer Res; 1979 Oct; 39(10):4048-54. PubMed ID: 476642
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of the 5'-triphosphates of arabinosylcytosine and 2',2'-difluorodeoxycytidine in L1210 cells.
Plunkett W; Grindey GB
Nucleic Acids Symp Ser; 1987; (18):77-9. PubMed ID: 3697155
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Hug V; Keating MJ; Chubb S
Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
[TBL] [Abstract][Full Text] [Related]
16. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
17. Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C.
Plunkett W; Keating M
Adv Exp Med Biol; 1986; 195 Pt B():171-5. PubMed ID: 3766228
[No Abstract] [Full Text] [Related]
18. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
Riva CM; Rustum YM
Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
[TBL] [Abstract][Full Text] [Related]
19. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.
Plunkett W; Liliemark JO; Estey E; Keating MJ
Semin Oncol; 1987 Jun; 14(2 Suppl 1):159-66. PubMed ID: 3589690
[No Abstract] [Full Text] [Related]
20. Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells.
Shewach DS; Mitchell BS
Cancer Res; 1989 Dec; 49(23):6498-502. PubMed ID: 2819707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
